



No.F.14-1/2022-PEC
Government of Pakistan
Drug Regulatory Authority of Pakistan
Prime Minister's National Health Complex,
Park Road, Chak Shahzad, Islamabad


Islamabad, the 22nd July, 2024

Subject: - **Decision of Registration Board for "Ciprofloxacin for Oral suspension"**.

I am directed to refer to the subject captioned above. Registration Board in its 331st meeting held on 31st Oct - 2nd Nov, 2023 deliberated the subject matter and decided as under:

"All registration holders of ciprofloxacin granules for oral suspension to whom registration has been granted with ciprofloxacin hydrochloride, should follow the USP monograph of "Ciprofloxacin for Oral suspension".

2. Accordingly, above decision of Registration Board is hereby circulated for compliance of all relevant stakeholders.



(Ammar Ashraf Awan)
Deputy Director (PE&R)

Distribution:

- i. Director (MIS), DRAP for uploading on DRAP's website.
- ii. Director, Central Drugs Laboratory, Karachi.
- iii. Chief, Drug Control and Traditional Medicine Division, National Institute of Health, Islamabad.
- iv. Director, Drug Testing Laboratories of the Punjab (Lahore, Faisalabad, Multan, Bahawalpur, Rawalpindi), Sindh, Khyber Pakhtunkhwa, Balochistan, AJ&K and Gilgit Baltistan.
- v. The Chief Drugs Controller/Inspector, Punjab / KPK / Sindh / Balochistan / ICT / AJ&K / Gilgit Baltistan.
- vi. Additional Director / Officer In-charge DRAP Karachi, Lahore, Islamabad, Peshawar, Quetta for circulation to pharmaceutical units located in their respective area of jurisdiction
- vii. Chairman, Pakistan Pharmaceutical Manufacturer's Association, Islamabad.
- viii. Executive Director, Pharma Bureau, Karachi.
- ix. Executive Director, PCDA, Karachi.

Copy for information to:

- a. PS to CEO, DRAP.
- b. PA to Director (PE&R)/Chairman, Registration Board.


Deputy Director (PE&R)